Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M. Folegatti, Alexander Batten, Mustapha Bittaye et al.|The Lancet|2020Cited by 2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie Ewer, Megan Baker, Jordan R. Barrett et al.|Nature Medicine|2020Cited by 643
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trialMehreen S. Datoo, Halidou Tinto, Hamtandi Magloire Natama et al.|The Lancet Infectious Diseases|2022Cited by 285
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling studyNora Schmit, Peter Winskill, Hillary M. Topazian et al.|The Lancet Infectious Diseases|2024Cited by 48